Sagimet Biosciences Inc. (SGMT) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Sagimet Biosciences Inc. (SGMT) closed at USD 7.55 on 2026-10-14, a change of -8.4 % over the past year, with a market capitalization of USD 579.32M.

Sagimet Biosciences Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Sagimet Biosciences Inc. key figures

Previous close

USD 7.55 (2026-10-14)

1-year change

-8.4 %

Market cap

USD 579.32M

Enterprise value

USD 269.65M

P/E ratio (trailing)

-6.29

P/E ratio (forward)

-6.28

EPS (trailing)

-1.30

EPS (forward)

-1.30

PEG ratio

n/a

Price to book

1.97

Revenue growth

n/a

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

8.34

Employees

16

Analyst consensus (third-party)

strong_buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Sagimet Biosciences Inc.

Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic and fibrotic pathways in the United States. The company's lead drug candidate is Denifanstat, an oral, once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction-associated steatohepatitis, acne, and select forms of cancer. It also develops TVB-3567, a FASN inhibitor for the treatment of acne indication; and other oncology programs, such as solid tumor and glioblastoma. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Sagimet Biosciences Inc. and compare it with other stocks.